Physician profile
Thomas P Smith
NPI 1205996980
$2,374.48
in general payments reported to CMS, 2019-2025
25 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $105 · 2021: $171 · 2022: $582 · 2023: $335 · 2024: $187 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $312.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.80 | 2019-2025 | Jardiance |
| Amgen INC. | $277.57 | 2019-2023 | Otezla, Repatha |
| Biotronik INC. | $266.41 | 2019-2022 | |
| Abbott Laboratories | $185.55 | 2019-2025 | Jot Dx |
| Janssen Pharmaceuticals, INC | $164.53 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $136.40 | 2023 | Optimizer |
| Pfizer INC. | $109.31 | 2020-2025 | |
| Baxter Healthcare | $109.14 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $96.15 | 2023-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $60.81 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.08 | 2020-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $41.33 | 2019-2024 | Farxiga |
| Tactile Systems Technology INC | $34.19 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Kiniksa Pharmaceuticals International, Plc | $26.67 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiofocus, INC. | $26.16 | 2019 | |
| Boston Scientific Corporation | $25.19 | 2022 | |
| Abbvie INC. | $25.18 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.71 | 2019 | |
| Lundbeck LLC | $17.52 | 2022 | |
| Dexcom, INC. | $17.33 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $17.26 | 2022 | |
| Medtronic, INC. | $14.18 | 2023 | Venaseal |
| Sanofi Pasteur INC. | $14.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.76 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.